Sosei Group Corporation has announced that its Japanese subsidiary, Sosei Co., Ltd., (“Sosei K.K.”) has signed a distribution agreement for commercialization of SO-1105 in Japan with FUJIFILM Pharma Co., Ltd (“FUJIFILM Pharma”).
SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. It has the potential to become the first long-acting, sustained-release treatment in tablet form for oropharyngeal candidiasis in Japan that could enhance patients’ compliance and quality of life.
SO-1105 was originally developed by a French pharmaceutical company, BioAlliance Pharma, which received its first marketing authorization for SO-1105 in France in October 2006.
SO-1105 has since been registered in 24 European countries, in South Korea, and in the United States, under the trade names Loramyc®/Oravig®. Sosei K.K. acquired exclusive development and commercialization rights in Japan from BioAlliance in May 2011.
Under the terms of the agreement with FUJIFILM Pharma, Sosei K.K. will be responsible for registration, manufacturing and supply, and FUJIFILM Pharma for marketing and distribution of SO-1105.
Based on this agreement, Sosei K.K. is entitled to receive a total of 900 million yen for key initial payment and achieved development and regulatory milestones, as well as margin on the sales of SO-1105 to FUJIFILM Pharma. Additional payments may also be received upon achievement of sales-based milestones.
We believe that the distribution agreement with FUJIFILM Pharma, which has expertise in infectious diseases, will help us expand the reach of SO-1105 to more oropharyngeal candidiasis patients.